Author

N. Dugot-Senant

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

V. Moreau· 3 shared A.-A. Raymond· 2 shared F. SALTEL· 2 shared J.-W. Dupuy· 2 shared N. Allain· 2 shared P. Bioulac-Sage· 2 shared A. Abou-Ammoud· 1 shared A. Brunel· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

V. Moreau

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma

C. Dantzer, J. Vache, A. Brunel, I. Mahouche, A.-A. Raymond, J.-W. Dupuy, M. Petrel, P. Bioulac-Sage, D. Perrais, N. Dugot-Senant, M. Verdier-Sage, B. Bessette, C. Billottet, V. Moreau

This study shows that oncogenic β-catenin reduces exosome release in HCC, leading to immune escape by decreasing immune cell infiltration.

bioRxiv · Oct 24, 2023Cancer Biology

The beta-catenin-target Fascin-1, altering hepatocyte differentiation, is a new marker of immature cells in hepatoblastomas

C. Gest, S. Sena, V. Neaud, R. Loesch, N. Dugot-Senant, L. Paysan, L. Piquet, T. Robbe, N. Allain, D. Dembele, C. Guettier, P. Bioulac-Sage, B. Le Bail, C. Grosset, F. SALTEL, , V. Moreau

The paper investigates the role of beta-catenin in hepatoblastomas, identifying Fascin-1 as a marker of immature cells linked to loss of hepatocyte differentiation.

bioRxiv · Apr 21, 2021Cancer Biology

Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switching

M. Sala, N. Allain, A. Jabouille, E. Henriet, A. Abou-Ammoud, A. Uguen, S. Di-Tommaso, D. Cyril, A.-A. Raymond, J.-W. Dupuy, E. Gerard, N. Dugot-Senant, B. Rousseau, J.-P. Merlio, A. Pham-Ledart, , F. Saltel

This study shows DDR2 drives melanoma drug resistance via AXL-dependent phenotype switching, suggesting DDR inhibition as a potential second-line treatment.

bioRxiv · Mar 26, 2021 · PreprintCancer Biology